Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Oncotarget · 2024
DOI: 10.18632/oncotarget.28547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, 2024. Verfasst von Ashley Del Dosso und 2 weiteren Autor:innen. Beteiligte Einrichtung: ONCOtherapeutics, West Hollywood, CA 90069, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Janus Kinase Inhibitors, Pyrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. Recently, the Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to have a role in the pathogenesis of MM. Preclinical studies have demonstrated a role for JAK signaling in direct and indirect growth of MM and downregulation of anti-tumor immune responses in these patients. Also, inhibition of JAK proteins enhances the anti-MM effects of other drugs used to treat MM. These findings have been confirmed in clinical studies which have further demonstrated the safety and efficacy of JAK inhibition as a means to overcome resistance to currently available anti-MM therapies. Additional studies will provide further support for this promising new therapeutic approach for treating patients with MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ONCOtherapeutics, West Hollywood, CA 90069, USA.
- Berenson Cancer Center, West Hollywood, CA 90069, USA.
- Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA.
Zitieren
APA
Del Dosso, A., Tadevosyan, E., & Berenson, J. R. (2024). Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. Oncotarget. https://doi.org/10.18632/oncotarget.28547
Vancouver
Del Dosso A, Tadevosyan E, Berenson JR. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. Oncotarget. 2024. doi:10.18632/oncotarget.28547
BibTeX
@article{DelDosso2024,
author = {Del Dosso, Ashley and Tadevosyan, Elizabeth and Berenson, James R},
title = {Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma},
journal = {Oncotarget},
year = {2024},
doi = {10.18632/oncotarget.28547}
}
EUVIMED